Heterocycles

Details Heterocycles Heterocycles

2011-01-04

2011-01-04

Balasubramanian, Venkataraman (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C544S326000, C544S328000, C544S333000, C544S335000, C544S122000, C544S060000, C514S256000, C514S269000, C514S274000

Reexamination Certificate

active

07863446

ABSTRACT:
Novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof are described. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell-damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors, and useful for treating PDE4 mediated diseases.

REFERENCES:
patent: 5166137 (1992-11-01), Otterlei et al.
patent: 5527546 (1996-06-01), Penza et al.
patent: 5580985 (1996-12-01), Lee et al.
patent: 5622977 (1997-04-01), Warrellow et al.
patent: 5712298 (1998-01-01), Amschler
patent: 5728704 (1998-03-01), Mylari et al.
patent: 6004813 (1999-12-01), Serlupi-Crescenzi et al.
patent: 6410563 (2002-06-01), Deschenes et al.
patent: 6410729 (2002-06-01), Spohr et al.
patent: 6420385 (2002-07-01), Spohr et al.
patent: 7317014 (2008-01-01), Agarwal et al.
patent: 2005/0107413 (2005-05-01), Agarwal et al.
patent: 2008/0207606 (2008-08-01), Srinivas et al.
patent: WO 99/50262 (1999-10-01), None
patent: WO 02/074298 (2002-09-01), None
patent: WO 03/084935 (2003-10-01), None
patent: WO 03/084938 (2003-10-01), None
patent: WO-2004/009560 (2004-01-01), None
patent: WO 2004/009560 (2004-01-01), None
patent: WO 2007/083182 (2007-07-01), None
Wolff Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Vippagunta et al., Advanced Drug Delivery Reviews 48: 3-26, 2001.
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Wang et al., Biochem. J. 408(Pt2), 193-201, 2007.
Boswell-Smith et al., British Journal of Pharmacology, 147, S252-S257, 2007.
Tracey et al., Pharmacology & Therapeutics, 117, 244-274, 2008.
Moser et al.; (1989); “Interleukin I and Tumor Necrosis Factor Stimulate Human Vascular Endothelial Cells to Promote Transendothelial Neutrophil Passage;”The American Society for Clinical Investigation, Inc.; vol. (83); pp. 444-455.
Haworth et al.; (1991); “Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α*;”Eur. J. Immunol.; vol. (21); pp. 2575-2579.
Brennan et al.; (1989); “Inhibitory Effect of the TNFα Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis;”The Lancet; vol. (2); pp. 244-247.
Arend et al.; (1995); “Inhibition of the Production and Effects of Interleukin-1 and Tumor Necrosis Factor α in Rheumatoid Arthritis;”Arthritis&Rheumatism; vol. (38); No. 2; pp. 151-160.
Goldenberg; (1999); “Etanercept, a Novel Drug for the Treatment of Patients with Severe, Active Rheumatoid Arthritis;”Clinical Therapeutics; vol. (21); No. 1; pp. 75-87.
Luong et al.; (2000)“Treatment Options for Rheumatoid Arthritis: Celecoxib, Leflunomide, Etanercept, and Infliximab;”The Annals of Pharmacotherapy; vol. (34); pp. 743-760.
Klein et al.; (1991) “Murine Anti-Interleukin-6 Monoclonal Antibody Therapy for a Patient With Plasma Cell Leukemia;”Blood; vol. (78); No. 5; pp. 1198-1204.
Lu et al.; (1992) “High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo*”Eur. J. Immunol.; vol. (22) pp. 2819-2824.
Chandrasekhar et al.; ( 1990) “Arthritis Induced by Interleukin-I is Dependent on the Site and Frequency of Intraarticular Injection;”Clinical Immunology and Immunopathology; vol. (55); pp. 382-400.
Firestein et al.; (1992); “Stromelysin and Tissue Inhibitor of Metalloproteinases Gene Expression in Rheumatoid Arthritis Synovium;”American Journal of Pathology; vol. (140); No. 6; pp. 1309-1314.
Dinarello; (1994); “The biological properties of interleukin-1;”Eur. Cytokine Netw.; vol. (5); No. 6; pp. 517-531.
Brahn et al.; (1992); “Effects of Tumor Necrosis Factor Alpha (TNF-α) on Collagen Arthritis;”Lymphokine and Cytokine Research; vol. (11); No. 5; pp. 253-256.
Cooper et al; (1992); “Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumor necrosis factor of transforming growth factor-beta;”Clin. Exp. Immunol.; vol. (89); pp. 244-250.
Kakazu et al.; (1999); “Type 1 T-Helper Cell Predominance in Granulomas of Crohn's Disease;”The American Journal of Gastroenterology; vol. (94); pp. 2149-2155.
Colpaert et al.; (2002); “In vitro analysis of IGN-gamme and IL-12 production and their effects in ileal Crohn's disease;”European Cytokine Network; vol. (13); pp. 431-437.
Berrebi et al.; (1998); “Interleukin-12 Expression is Focally Enhanced in the Gastric Mucosa of Pediatric Patients with Crohn's Disease;”American Journal of Pathology; vol. (152); pp. 667-672.
Parronchi et al. (1997); “Type 1 T-Helper Cell Predominance and Interleukin-12 Expression in the Gut of Patients with Crohn's Disease;”American Journal of Pathology; vol. (150); pp. 823-832.
Monteleone et al. (1997); “Interleukin 12 is expressed and actively release by Crohn's disease intestinal lamina propria mononuclear cells;”Gatroenterology; vol. (112); pp. 1169-1178.
Nielsen et al. (2003); “Upregulation of Interleukin-12 and -17 in Active Inflammatory Bowel Disease;”Scand J Gastroenterol; vol. (38); pp. 180-185.
Patrignani et al.; (1994); “Biochemical and Pharmacological Characterization of the Cyclooxgygenase Activity of Human Blood Prostaglandin Endoperoxide Synthases;”The Journal of Pharmacology and Experimental Therapeutics; vol. (271); No. 3; pp. 1705-1712.
Warner et al.; (1999); “Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis;”Proc. Natl. Acad. Sci.; vol. (96); pp. 7563-7568.
Xie et al.; (1991); “Expression of a Mitogen-Responsive Gene Encoding Prostaglandin Synthase is Regulated by mRNA Splicing;”Proc. Natl. Acad. Sci.; vol. (88); pp. 2692-2696.
Maxey et al.; (1992); “Interference in Enzyme Immunoassays;”Journal of Clinical Immunoassay; vol. (15); No. 2; pp. 116-120.
Jansky et al.; (2003); “Dynamics of Cytokine Production in Human Peripheral Blood Mononuclear Cells Stimulated by LPS or Infected byBorrelia:” Physiological Research; vol. (52); pp. 593-598.
Dauksas et al.; (1993); “Synthesis and Anti-inflammatory Properties of Benzoyl, Halogenbenzoyl or Cinnamoyl Substituted 1-Benzoxepanes and 2-methyl-benzoxolanes;”Arzneim-Forsch/Drug Res.; vol. (43); No. 1; pp. 44-50.
Romano et al.; (1992); “Transforming Growth Factor α Protection against Drug-induced Injury to the Rat Gastric Mucosa in Vivo;”The Journal of Clinical Investigation; vol. (90); pp. 2409-2421.
Theisen-Popp et al.; (1994); “Antirheumatic drug profiles evaluated in the adjuvant arthritis of rats by multiparameter analysis;”Agent Actions; vol. (42); pp. 50-55.
Fletcher et al.; (1998); “Therapeutic Admini

Affiliated with

Also associated with

Rating

Heterocycles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocycles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocycles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2654100